The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients
Abstract Background Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia. Although potent drugs are emerging, CML and AML may still relapse after the drug treatment is stopped. N6-methyladenosine (m6A) and lncRNAs play certain roles in the oc...
Main Authors: | Li-Rong Yang, Zhu-Ying Lin, Qing-Gang Hao, Tian-Tian Li, Yun Zhu, Zhao-Wei Teng, Jun Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-01-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-021-02428-3 |
Similar Items
-
Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma
by: Xia-Qing Li, et al.
Published: (2024-01-01) -
m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD
by: Feng Xu, et al.
Published: (2021-06-01) -
The role of lncRNAs and exosomal lncRNAs in cancer metastasis
by: Yutong Zhang, et al.
Published: (2023-09-01) -
Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma
by: Wentao Lin, et al.
Published: (2024-02-01) -
N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma
by: Zhongguang Wu, et al.
Published: (2022-01-01)